Cytos Biotechnology AG Plans to Sell Rights to Hypertension Vaccine

August 20, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Aug. 20 (Bloomberg) -- Cytos Biotechnology AG, the Swiss developer of vaccines against allergies and nicotine addiction, expects to sell rights to an experimental treatment for hypertension in the second half of next year.

Twitter
LinkedIn
Facebook
Email
Print

Mergers & acquisitions